Thu, 02 Jul 2009 16:38:08 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/haematology/podcast_HematologyCME-CNE-CPE_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology no PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest advances in the treatment of multiple myeloma, with a focus on appropriate and clinically relevant endpoints for assessing the benefit of new therapies, and results of recent clinical trials to determine if these newer agents have convincingly demonstrated improvements in efficacy. http://podcast.peerviewpress.com/haematology/PA05541FCr440.mp3 http://podcast.peerviewpress.com/haematology/PA05541FCr440.mp3 Thu, 02 Jul 2009 16:19:13 -0400 Science, Medicine no 00:23:51 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05541FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05541FCCMEinfo.pdf Thu, 02 Jul 2009 16:19:10 -0400 Science, Medicine no 00:00:00 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in management of CKD-related anemia discuss the inflammatory and other mechanisms that affect hemoglobin variability and hyporesponsiveness, as well as strategies to achieve optimal hemoglobin levels. http://podcast.peerviewpress.com/haematology/PPVNE05896FCe031.mp3 http://podcast.peerviewpress.com/haematology/PPVNE05896FCe031.mp3 Fri, 26 Jun 2009 15:22:17 -0400 Science, Medicine no 00:29:30 CKD, chronic kidney disease, anemia, CKD anemia, kidney disease PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PPVNE05896FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PPVNE05986FCCMEinfo.pdf Fri, 26 Jun 2009 15:22:14 -0400 Science, Medicine no 00:00:00 CKD, chronic kidney disease, anemia, CKD anemia, kidney disease PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in multiple myeloma bone health management discuss the development and clinical impact of myeloma bone disease and the identification of several promising therapeutic targets within the bone microenvironment. Several other topics will be addressed, including the current recommendations for bone disease assessment and management, as well as the potential role of novel therapies with bone protective aspects. http://podcast.peerviewpress.com/haematology/PA05569FCr447.mp3 http://podcast.peerviewpress.com/haematology/PA05569FCr447.mp3 Fri, 22 May 2009 15:48:00 -0400 Science, Medicine no 00:24:11 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05569FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05569FCCMEinfo.pdf Fri, 22 May 2009 15:47:57 -0400 Science, Medicine no 00:00:00 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in MCL discusses the characteristics of this relatively rare and clinically challenging disease, including its natural course and typical unresponsiveness to most front-line treatment options. The nature of resistant disease will also be profiled, and the activity of a novel generation of therapeutics in previously treated patients will be evaluated. http://podcast.peerviewpress.com/haematology/PA05230FCn208.mp3 http://podcast.peerviewpress.com/haematology/PA05230FCn208.mp3 Wed, 13 May 2009 10:17:58 -0400 Science, Medicine no 00:18:52 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05230FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05230FCCMEinfo.pdf Wed, 13 May 2009 10:17:56 -0400 Science, Medicine no 00:00:00 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in the management of adults with hemophilia and inhibitors discuss the diagnosis and treatment of allo- and autoantibodies, as well as future directions for managing patients with hemophilia and inhibitors. http://podcast.peerviewpress.com/haematology/PA05327FCe027.mp3 http://podcast.peerviewpress.com/haematology/PA05327FCe027.mp3 Thu, 30 Apr 2009 14:24:33 -0400 Science, Medicine no 00:54:23 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://podcast.peerviewpress.com/haematology/PA05327FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05327FCCMEinfo.pdf Thu, 30 Apr 2009 14:24:29 -0400 Science, Medicine no 00:00:00 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in iron overload discusses the differences between hereditary and transfusional hemochromatosis, and evaluates the role of iron chelation in the management of the latter, including both single-agent and combination approaches. New data on the ability of chelators to reduce cardiac iron burden in patients with transfusional iron overload are also discussed. http://podcast.peerviewpress.com/oncology/PA05130FCn202.mp3 http://podcast.peerviewpress.com/haematology/PA05130FCn202.mp3 Wed, 22 Apr 2009 11:38:43 -0400 Science, Medicine no 00:23:04 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05130FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05130FCCMEinfo.pdf Wed, 22 Apr 2009 11:38:40 -0400 Science, Medicine no 00:00:00 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Experts in MDS and AML discuss the clinical importance of new findings in these settings, specifically the following topics: an evaluation of modified induction/consolidation chemotherapy in AML, an update on epigenetic treatment and the potential of epigenetic combinations to augment activity in MDS and AML, and the relevance of newer prognostic models to a well-rounded clinical approach. Faculty will also discuss new data on the mechanisms of epigenetic agents, and whether these data possess prognostic or predictive implications. http://podcast.peerviewpress.com/haematology/PA05351FCs514.mp3 http://podcast.peerviewpress.com/haematology/PA05351FCs514.mp3 Tue, 03 Mar 2009 15:09:44 -0500 Science, Medicine no 00:39:11 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05351FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05351FCCMEinfo.pdf Tue, 03 Mar 2009 15:09:42 -0500 Science, Medicine no 00:00:00 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, a leading hematologist-oncologist will lead participants through 2 case scenarios in diverse CML settings and illustrate important aspects of disease management. The first case will detail appropriate therapy selection in a newly diagnosed patient with CML and consider the nuances of patient care at various time points to illustrate proper long-term treatment and other issues, including safety related to the extended use of tyrosine kinase inhibitor therapy. The second case will focus on the second-line CML setting, and develop an interactive scenario centered on therapeutic decision points, including appropriate agent selection in the face of specific mutational status or patient characteristics with implications for safe administration of therapy. http://podcast.peerviewpress.com/haematology/PA05123FCp150.mp3 http://podcast.peerviewpress.com/haematology/PA05123FCp150.mp3 Wed, 26 Nov 2008 11:31:12 -0500 Science & Medicine no 00:22:07 imatinib, nilotinib, dasatinib, TKI, CML, growth-factor support, hematologic reponse, CCyR, MMR PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05123FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05123FCCMEinfo.pdf Wed, 26 Nov 2008 11:30:59 -0500 Science & Medicine no 00:00:00 imatinib, nilotinib, dasatinib, TKI, CML, growth-factor support, hematologic reponse, CCyR, MMR PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, a leading hematologist-oncologist discusses the integration of novel regimens in the clinical spectrum of treatment for patients with multiple myeloma. After a brief review of standard induction therapies for patients undergoing stem-cell transplant, the discussion will move on to review updated safety and efficacy data on regimens that contain immunomodulating therapies or proteasome inhibitors. Other topics of discussion in upfront settings will include the feasibility of prolonged front-line therapy, stem cell collection, early treatment, and maintenance therapy. The activity will conclude with a discussion of treatment in relapsed/refractory myeloma, including an evaluation of both established and emerging agents. http://podcast.peerviewpress.com/haematology/PA05171FCn198.mp3 http://podcast.peerviewpress.com/haematology/PA05171FCn198.mp3 Mon, 29 Sep 2008 16:41:06 -0400 Science & Medicine no 00:23:06 multiple myeloma, relapsed, refractory, induction, upfront, Thal-Dex, bortezomib, IMiD, stem cell PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA05171FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA05171FCCMEinfo.pdf Mon, 29 Sep 2008 16:41:01 -0400 Science & Medicine no 00:00:00 multiple myeloma, relapsed, refractory, induction, upfront, Thal-Dex, bortezomib, IMiD, stem cell PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma. http://podcast.peerviewpress.com/haematology/PA04421FCr392.mp3 http://podcast.peerviewpress.com/haematology/PA04421FCr392.mp3 Thu, 04 Sep 2008 16:35:29 -0400 Science & Medicine no 00:44:52 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04421FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04421FCCMEInfo.pdf Thu, 04 Sep 2008 16:35:29 -0400 Science & Medicine no 00:00:00 Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert in the management of venous thromboembolism (VTE) presents recent data on therapies used to treat this condition, focusing on patients with malignancies. The different guidelines for management of this condition will be briefly reviewed. Diagnosis of this condition is also highlighted. http://podcast.peerviewpress.com/haematology/PA04763FCn185.mp3 http://podcast.peerviewpress.com/haematology/PA04763FCn185.mp3 Wed, 03 Sep 2008 14:24:11 -0400 Science & Medicine no 00:33:17 VTE, cancer, PE, thrombosis, bleeding, DVT, NCCN, unfractionated heparin, warfarin, LMWH, VKA PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04763FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04763FCCMEinfo.pdf Wed, 03 Sep 2008 14:24:09 -0400 Science & Medicine no 00:00:00 VTE, cancer, PE, thrombosis, bleeding, DVT, NCCN, unfractionated heparin, warfarin, LMWH, VKA PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed. http://podcast.peerviewpress.com/haematology/PA04328FCe015.mp3 http://podcast.peerviewpress.com/haematology/PA04328FCe015.mp3 Thu, 17 Jul 2008 09:35:24 -0400 Science & Medicine no 00:40:15 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04328FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04328FCCMEinfo.pdf Thu, 17 Jul 2008 09:34:24 -0400 Science & Medicine no 00:00:00 CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. http://podcast.peerviewpress.com/haematology/PA04356FCr372.mp3 http://podcast.peerviewpress.com/haematology/PA04356FCr372.mp3 Mon, 12 May 2008 14:31:22 -0400 Science & Medicine no 00:33:15 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04356FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04356FCCMEinfo.pdf Mon, 12 May 2008 14:30:24 -0400 Science & Medicine no 00:00:00 Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert in hematology discusses clinical issues and latest evidence of diagnosis and treatment of MDS. http://podcast.peerviewpress.com/haematology/PA04357FCn175.mp3 http://podcast.peerviewpress.com/haematology/PA04357FCn175.mp3 Mon, 24 Mar 2008 16:33:33 -0400 Science & Medicine no 00:52:43 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04357FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04357FCCMEinfo.pdf Mon, 24 Mar 2008 16:33:30 -0400 Science & Medicine no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options. http://podcast.peerviewpress.com/haematology/PA04297FCr364.mp3 http://podcast.peerviewpress.com/haematology/PA04297FCr364.mp3 Thu, 28 Feb 2008 16:31:07 -0500 Science & Medicine no 00:37:22 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA04297FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA04297FCCMEinfo.pdf Thu, 28 Feb 2008 16:31:04 -0500 Science & Medicine no 00:00:00 acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents. http://podcast.peerviewpress.com/haematology/PA03696FCr324.mp3 http://podcast.peerviewpress.com/haematology/PA03696FCr324.mp3 Tue, 24 Jul 2007 10:35:13 -0400 Science & Medicine no 00:36:59 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/haematology/PA03696FCCMEinfo.pdf http://podcast.peerviewpress.com/haematology/PA03696FCCMEinfo.pdf Tue, 24 Jul 2007 10:34:50 -0400 Science & Medicine no 00:00:00 Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion